More than 200 companies went public in 2025, a 36.5% increase from the previous year. Nonetheless, the rebound fell short of what many expected despite unicorn IPO stocks such as FigmaFIG and Circle ...

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 to $17 per share. The California biotech announced its IPO intentions ...

Checking in on our late-stage bull market scorecard… new IPO madness… margin debt hits record highs… the single-stock ETF explosion… why we’re still dancing (but closer to the exit) Last fall, we ...